Research Radartracking 1,138 published studies · 277 human · 6 safety signals · 42 clinical trials · 44 cancer pages · updated Jul 2026Open the Research Map →

← Melanoma

Melanoma: treatment map

Standard care plus compounds studied in the literature, organized by clinical readiness.

Educational only. This is not medical advice and not a recommendation. Confirm anything here with your oncology team.

Treatment map: Melanoma

Standard care plus every compound studied in the literature (each cited) and graded by evidence, organized by clinical readiness. A category, not a verdict that anything works — confirm anything here with your oncology team.

64
Interventions
0
Standard of care
40
Tested in people
0
Lab / animal
18
Named in lit.
7
Classes
Standard of care (0) Guideline option (6) Tested in people (40) Lab / animal only (0) Named in the literature (18)

Tested in people, by trial phase: phase not reported ×40

Clinical evidence
Preclinical evidence
Standard of care
Guideline option
Tested in people
Lab / animal only
Named in the literature
Surgery & procedures
—
—
6
—
5
Radiotherapy
—
—
2
—
1
Chemotherapy
—
—
1
—
1
Targeted therapy
—
—
8
—
6
Immunotherapy
—
6
19
—
4
Repurposed drugs
—
—
1
—
—
Other
—
—
3
—
1

Columns group into clinical evidence (used in, or tested on, people) and preclinical evidence (lab/animal, or only named in the literature). Cell = number of interventions; a dashed cell means none recorded there.

Established care — detail (6)
Immunotherapy
pembrolizumabRecurrent or later-line
FDA-approved for this cancer.
—Guideline option
pembrolizumabAdjuvant (after surgery)
FDA-approved for this cancer.
—Guideline option
pembrolizumabNeoadjuvant (before surgery)
FDA-approved for this cancer.
—Guideline option
pembrolizumabAdjuvant (after surgery) · BRAF wild-type cutaneous melanoma
FDA-approved for this cancer.
—Guideline option
pembrolizumabBRAF wild-type cutaneous melanoma
FDA-approved for this cancer.
—Guideline option
pembrolizumab
FDA-approved for this cancer.
—Guideline option
Investigational & adjunct compounds — detail (58)
Meta-analysis (40)
Anti-LAG-3 antibodiesAntibiotics, proton pump inhibitors (PPIs), and probioticsbeta-blockersbiopsycancer vaccine therapychemotherapydabrafenib + trametinibdabrafenib and trametinib· Adjuvant (after surgery) · BRAF-mutantdabrafenib/trametinib· BRAF-mutantdarovasertib (NVP-LXS196)effector T-cell therapyencorafenib/binimetinib· BRAF-mutantentinostathigh-dose interferon· Adjuvant (after surgery)immune checkpoint inhibitorsImmune checkpoint inhibitors (CTLA-4/PD-1/PD-L1)ipilimumabipilimumab + nivolumabipilimumab or nivolumabipilimumab plus nivolumab· BRAF wild-type cutaneous melanomaipilimumab plus nivolumab· BRAF-mutantlabial reconstructionliver-directed regional therapiesMohs micrographic surgerymRNA-4157/V940 plus pembrolizumabmultimodality treatmentnivolumab· Adjuvant (after surgery) · BRAF wild-type cutaneous melanomanivolumab· BRAF wild-type cutaneous melanomanivolumabnivolumab + ipilimumab· First-line (advanced disease)proton technique with IMRTproton therapy (SFUD)pucotenlimabselumetinib; trametinibstandard surgical excisionsurgerysystemic glucocorticoidstebentafusp· HLA-A*02:01tumor-infiltrating lymphocytes (TIL)vemurafenib/cobimetinib· BRAF-mutant
Named in the literature
Conventional chemotherapyInterferon-α· Adjuvant (after surgery)interferon-alpha· Adjuvant (after surgery)nivolumab· Adjuvant (after surgery)nivolumab plus low-dose ipilimumab· Adjuvant (after surgery)systemic medical treatmentexcision with 2 mm marginsentinel lymph node dissectionSentinel lymph node dissection (SLND/SLNB)Surgical excision (wide local excision)surgical excision with 1–2 cm marginsAdjuvant radiation· Adjuvant (after surgery)Dabrafenib· BRAF V600 mutationsdabrafenib plus trametinib· Adjuvant (after surgery) · BRAF-mutated melanomaDabrafenib + Trametinib· BRAF V600 mutationsTrametinib· BRAF V600 mutationsVemurafenib· BRAF mutatedvemurafenib plus cobimetinib· BRAF-mutated melanoma

"Tested in people" rows show the highest trial phase found in that compound's cited human studies (Phase I–IV; "phase not reported" = a human study with no phase tag). "Studied" = named in the cited literature for this cancer. "FDA ✓" = FDA-approved for this cancer; "off-label" = an FDA-approved drug used outside its approved indications (per openFDA). Not a claim that anything works.